Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for September 9, 2022

9/9/2022

 
The FDA approved spesolimab (Spevigo, Boehringer Ingelheim), on 9/1/2022, for the treatment of generalized pustular psoriasis flares.
 
The FDA approved daxibotulinumtoxin (Daxxify, Revance Therapeutics), on 9/8/2022, for the temporary improvement in the appearance of moderate to severe glabellar lines. Daxibotulinumtoxin was approved with a back box warning regarding the potential for the toxin affect to spread beyond the injection site.
 
The FDA’s review of AMX0035 for the March 2022 AdComm meeting and a new review for the September 2022 AdComm meeting both found the NDA did not provide enough evidence to support approval. The second review noted the revised NDA contained the same survival data with a different analysis. The review suggested that the 48-week, 600 patient, Phase III, PHOENIX trial should have data by late 2023 or early 2024 would give a better indication of the affect of AMX0035 on ALS. The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC) voted 6-4 to reject AMX0035 in March 2022 and recommended an additional trial to evaluate efficacy. The FDA extended the PDUFA date by three months to 9/29/2022. The PCNSDAC voted 7 to 2 to recommend approval of AMX0035 to treat ALS in September 2022.
 
The FDA accepted the re-submitted BLA for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastases from neuroblastoma and set a PDUFA date for 11/30/2022. The FDA’s Oncologic Drugs Advisory Committee will meet on 10/28/2022 to review omburtamab.
 
Ascendis Pharma has submitted an NDA for TransCon PTH to treat hypoparathyroidism.
 
The FDA halted the Phase II MOMENTUM trial, in June 2022, due to a serious occurrence of hypomagnesemia and requested a risk mitigation and safety monitoring plan. The hold was removed in September 2022 after changes to the study protocol.
 
Tarsas submitted an NDA for lotilaner ophthalmic solution for the treatment of Demodex blepharitis.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.